Fig. 2: Identification of extracellular vesicle (EV) candidate expression during early carboplatin treatment in HGSOC mouse models. | Oncogene

Fig. 2: Identification of extracellular vesicle (EV) candidate expression during early carboplatin treatment in HGSOC mouse models.

From: Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer

Fig. 2

A BALB/c nude mice were intrabursal-injected with platinum-resistant HGSOC cells (TR127), recapitulating the clinical presentation of HGSOC with aggressive ovarian tumor growth and metastatic spread to the mesentery, diaphragm, and pelvic regions. After tumor growth confirmation at the 2nd week, intraperitoneal carboplatin (CP, 2 mg/kg) treatment was administered for 5 weeks. B Mouse serum samples were collected at the end of each treatment cycle before the subsequent CP cycle, and EV protein expression was assessed using ELISA (n = 4; **p ≤ 0.005; *p ≤ 0.01 compared to pre-CP treatment or the 1st cycle of CP treatment). C–E Evaluation of candidate proteins TMEM205, CFH, CD1B, and FAS with established biomarkers CA125, HE4 and Mesothelin in HGSOC patient serum and serum-derived extracellular vesicles (EVs) using ELISA. This analysis was conducted on samples from both PS and PR samples in a training cohort of n = 12 patients, ** revealing statistically significant differences (p < 0.001).

Back to article page